On May 6, 2026, a thematic symposium on "Deep Integration of Industry, Academia, and Research" was held at the Anti-Aging Research Institute of Shenyang Pharmaceutical University, bringing together the institute and Shenzhen Cell Valley Group. The two sides conducted in-depth discussions on research collaboration, result translation, clinical research, talent development, and industrial implementation in the field of cell therapy, aiming to leverage the respective strengths of a university research platform and a cell therapy industry platform to explore a full-chain collaborative innovation model covering "basic research – technology development – clinical research – industrial translation."

The symposium was chaired by Gao Mingyu, Deputy Director of the Education, Science, Health and Sports Committee of the Liaoning Provincial Committee of the Chinese People's Political Consultative Conference (CPPCC), former Party Secretary of Shenyang Pharmaceutical University, and Dean of the Anti-Aging Research Institute of Shenyang Pharmaceutical University. Attendees from Shenzhen Cell Valley Group included Shi Yuanyuan, Chairman and General Manager; Tang Xiaomeng, Deputy General Manager; Wang Lei, Business Lead of the subsidiary Shenyang Cell Valley; as well as Kang Shuangming, Partner of Shanghai Huayi Capital and Chairman of Shenzhen Hongming Technology Consulting. Representing Shenyang Pharmaceutical University were Zhang Rong, Deputy Dean of the Anti-Aging Research Institute, Head of the Cell Center, Director of the Scientific Research Department, and Dean of the School of Life Sciences and Biopharmaceutics; along with responsible leaders from the Center for Food and Medicine Homology Research, the Supervision Office, the Education Foundation, and the Technology Transfer Center.

During the symposium, the two sides focused on academic exchange, research collaboration, and talent development in the cell therapy field. Participants agreed that cell and gene therapy, emerging biomedical technologies, and anti-aging medicine are at a critical juncture of rapid development and standardized translation, and that synergy among high-level research institutions, clinical resources, and industry platforms has become a key pathway for moving innovative outcomes toward clinical application and industrial implementation.

Dean Gao Mingyu noted that as a one-stop, full-chain service platform in the domestic cell and gene therapy sector and a clinical translation platform for emerging biomedical technologies, the Cell Valley Group has long been deeply engaged in viral vectors, immune cells, stem cells, exosomes, and related quality control systems. It has accumulated systematic practical experience in GMP-grade manufacturing, clinical research support, hospital collaboration, project translation, and regional platform development. The Anti-Aging Research Institute of Shenyang Pharmaceutical University, in turn, draws on the university's disciplinary foundations and research resources in pharmacy, life sciences, biopharmaceutics, and technology transfer, possessing solid research accumulation in anti-aging studies, cell technology research, food and medicine homology research, and biomedical innovation.

The exchange laid a solid foundation for the two parties to establish a regular cooperation mechanism going forward. In the future, the Cell Valley Group will actively promote pragmatic collaboration with the Anti-Aging Research Institute on joint applications for research projects, development of cell therapy and anti-aging technologies, translation of research outcomes, clinical research coordination, joint talent training, and industry platform construction—driving more innovative outcomes with clinical value and industrial potential from the laboratory to the clinic and the market.

Shi Yuanyuan stated that the symposium would serve as a launching point to further strengthen industry-academia-research synergy with the institute, fully leveraging their complementary strengths in research, technology, platforms, clinical translation, and industrial resources. Focusing on the intersection of cell therapy and anti-aging medicine, the two sides aim to jointly create a demonstration model for the translation of university research outcomes and the clinical application of emerging biomedical technologies, contributing to the high-quality development of the cell and gene therapy industry in Northeast China and beyond.